||Dr. Dieplinger studied technical chemistry at the Technical University of Graz, and medical biochemistry and medicine at the University of Graz in Austria. Thereafter, he became Assistant Professor at the Institute for Medical Biochemistry at the University of Graz. He continued his research at the Cardiovascular Research Institute of the well-regarded University of California in San Francisco, USA, and additionally at the EMBL in Heidelberg, Germany.
Presently he works as Associate Professor at the Department of Medical Biology and Human Genetics at the Medical University of Innsbruck, Austria. His expertise is in the areas of biochemistry, genetics, and metabolism of lipoproteins and vitamin E, with a recent focus on proteomics technologies. Until 2003, he held the position of Secretary of the European Lipoprotein Club (ELC), a non-profit international scientific organization and serves currently as president of the Austrian Atherosclerosis Society (AAS). He has authored more than 100 publications in peer-reviewed journals. Dr. Dieplinger currently holds a dual position as CEO and CSO of Vitateq. He oversees and is responsible for quality control, organization, R&D progress, scientific consultation, and execution of research projects, with the goal of commercializing the products at the highest level of quality, time efficiency, and profitability.